secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sharps Technology Inc. (STSS)
CIK:        0001737995
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001493152-22-035248
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sharps Technology enters exclusive U.S. distribution agreement with Nephron Pharmaceuticals for syringe products
--------------------------------------------------------------------------------

- Distribution agreement appoints Nephron as exclusive U.S. distributor for Sharps' syringe products.
- First products expected available by end of January 2023; initial revenue anticipated in first half of 2023.
- Agreement supports previously announced Inject-EZ startup in South Carolina, expected to begin in early 2023.
- Two-year term, with 30-day termination notice by either party for any reason.
- Nephron's sales network includes over 3,000 customers via direct and online channels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737995/000149315222035248/0001493152-22-035248-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737995/000149315222035248/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035248

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer